Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let'

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensu

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analys

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a like

Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform

Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the un

ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the un

Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions,

NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic

Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash run

Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher d

U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announ

uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related se

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutic

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.12) per share which missed the anal

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) d

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID He

Wedbush analyst Laura Chico reiterates Ovid Therapeutics (NASDAQ:OVID) with a Outperform and main

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transc

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceuti

Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy

Wedbush analyst Laura Chico maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raise

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal o

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

OV329 may be safer and more potent than existing treatments. A $60M private placement will fund furt

Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohor

Ovid Therapeutics shares climb after positive epilepsy data, new trial launch, and $60 million fundi

New York and California are stockpiling an alternative abortion medication in case a Texas judge&#

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned

  Tuesday's session saw 184 companies set new 52-week lows.

  On Monday, 160 companies hit new 52-week lows.